14 hepatitis B vaccine recipients who showed high titers of anti-hepatitis B surface antibodies in serum after booster immunization with a polyvalent hepatitis B surface antigen vaccine that contained trace amounts of hepatitis B virus (HBV) preS1 and preS2 envelope antigens were studied for their in vitro T cell response to these antigens. All 14 subjects displayed a significant proliferative T cell response to the S/p25 envelope region encoded polypeptide; 8 also responded to preS1, while only 1 showed a significant level of T cell proliferation to preS2. Limiting dilution analysis demonstrated that the frequency of preSspecific T cells in two of these vaccine recipients was higher than that of S/p25-specific T cells. T cell cloning was then performed and a total of 29 HBV envelope antigen-reactive CD4+ cloned lines were generated from two preS-responsive vaccines. 21 of these lines were S/p25 specific, 7 preS1 specific, and 1 preS2 specific. Taken together, all these results suggest that the preS1 antigen may function as a strong T cell immunogen in man.
Introduction
Existing vaccines against hepatitis B consist of either 20 nm hepatitis B surface antigen (HBsAg)' particles derived from plasma of chronic HBsAg carriers (1) , or HBsAg produced by recombinant DNA technology (2) .
Several lines of evidence suggest that inclusion of the preS sequence of the hepatitis B virus (HBV) envelope into these immunogens should improve the efficacy of the vaccination, inducing a wider spectrum of antiviral antibodies.
Since the preSl and preS2 regions of the HBV envelope may contain the hepatocyte receptor binding site (3, 4) , the immune response to these antigens may play an important role in the prevention of and recovery from HBV infection. In support of this hypothesis, it has been shown that anti-preS and anti-preS2 antibodies appear early during HBV infection, before the detection of anti-hepatitis B surface antibodies 1. Abbreviations used in this paper: anti-HBs, anti-hepatitis B surface antibodies; APC, antigen-presenting cells; ARC, antigen responsive cells; h, human; HBcAg, hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; r, recombinant; SI, stimulation index; TT, tetanus toxoid.
(anti-HBs; [5] [6] [7] [8] [9] . Their appearance is usually followed by recovery from HBV infection. In contrast, anti-preS antibodies are exceptionally rare in chronic hepatitis B (6, 7) . In addition, immune response to preS antigens may circumvent nonresponsiveness to the S region of HBV envelope in strains of HBsAg nonresponder mice (10) (11) (12) ; furthermore, chimpanzees immunized with a synthetic preS2 peptide appeared to be protected from HBV infection (13) .
Because the Pasteur vaccine (Hevac-B) contains small quantities of preS sequences (< 20 ng/f.g HBsAg; 14) , production of anti-preS antibodies in recipients of this vaccine has been investigated, and the results of such studies suggest that the preS antigens are highly immunogenic in man at least in terms of specific antibody elicitation (9, 15) . In contrast, very little is known about the human T cell response to preS antigens after vaccination or natural HBV infection (16) (17) (18) (19) (20) .
In the present study the T cell response to the S, preS2, and preSI antigens ofthe HBV envelope has been studied in recipients of the Pasteur vaccine using a series of well-characterized plasma-derived and recombinant antigen preparations consisting of various combinations of HBV envelope region encoded polypeptides. Our data show that immunization with very low amounts of preS 1 may induce in some individuals high levels of T cell sensitization, suggesting that the preS 1 molecule may function as a strong T cell immunogen in man. 14 subjects immunized with plasma-derived hepatitis B vaccine (Hevac-B; Pasteur), without anamnestic, biochemical, or immunological evidence of previous exposure to HBV, were studied. Control experiments were performed on 15 age-and sex-matched healthy, nonimmunized subjects who were negative for HBsAg, anti-HBs, and antibody to hepatitis B core antigen. HBsAg, anti-HBs, and antibodies to hepatitis B core antigen were determined by commercially available enzyme immunoassay kits (Abbott Laboratories, North Chicago, IL).
Methods
HBV envelope antigen preparations. A purified preparation containing the S, preS 1, and preS2 region encoded determinants was provided by Sorin Biomedica (Saluggia, Italy), and obtained from pooled HBsAg-positive serum of ad and ay subtypes derived from chronic HBsAg carriers as previously described (16) . By solid-phase RIA, levels ofpreS2 and preS 1 reactivities in this antigen preparation were about 8 and 1% ofthe total HBsAg reactivity, respectively. We will refer to this antigen as human (h) S+preS2+preSl.
Two plasma-derived preparations of HBsAg of different subtype (ad or ay) composed exclusively of the 25-kD S region encoded polypeptide (S/p25) without preS region encoded determinants (21), were provided by R. Louie (Cutter Laboratories, Berkeley, CA). They are herein designated as hS/p25. A recombinant, yeast-derived preparation of HBsAg(ay) containing the S/p25 polypeptide exclusively was provided by Amgen (Thousand Oaks, CA) and is herein designated as recombinant (r) S/p25. Two recombinant, yeast-derived preparations containing either S/p25 plus preS2 (rS+preS2; subtype ad; 22) or S/p25 plus preS2 plus preSI (rS+preS2+preS1; subtype ay; 23) and two synthetic peptides consisting of either the entire preS1 region (108 amino acid residues, subtype ay) or the entire preS2 region (55 amino acids, subtype ad) were provided by R. W. Ellis (Merck Sharp and Dohme Research Laboratories, West Point, PA).
Recombinant hepatitis B core antigen (HBcAg; Sorin Biomedica, Saluggia, Italy) and tetanus toxoid (TT; Massachusetts State Department of Public Health) were used as control antigens.
Isolation ofHBV envelope antigen-reactive T cell lines and clones. PBMC were cultured in RPMI 1640 medium supplemented with 25 mM Hepes, 2 mM L-glutamine, 50 ug/ml gentamycin, and 10% heatinactivated human AB-positive serum (complete medium) in the presence of hS+preS2+preS I (I jug/ml). After 7 d incubation at 37°C in a humidified atmosphere of 5% CO2 in air, activated lymphocytes were initially plated at 10 cells/well in round-bottomed, 96-well plates in RPMI 1640 medium containing 10% FCS in the presence of HBV envelope antigens (hS+preS2+preSl; 1 Ag/ml), rIL-2 (Hoffman La Roche, Basel, Switzerland), and mytomicin C-treated (45 min at 37°C; 50 ug/ml) autologous PBMC as antigen-presenting cells (APC; 1 X 105/well). Growing cloned T cell lines were expanded in medium containing rIL-2 and restimulated weekly with antigen and autologous APC.
Selected cloned T cell lines were subcloned at the concentration of 0.5 cells/well as described above.
The probability for each positive well being a clone derived from a single precursor was calculated by means of a conditional probability argument (24) assuming Poisson statistics (25) .
Tcellproliferation assay. For the study ofthe proliferative response of purified peripheral blood T cells to HBV envelope antigens, T cells and non-T cells were isolated by the E-rosette technique ( 16) .
Purified T cells (1 X 105) cocultured with 1 X 104 mytomicin C-treated autologous non-T cells as APC were incubated in complete medium for 7 d at 37°C in an atmosphere of 5% CO2 and 95% air in the presence of different concentrations (0.01, 0.1, or 1 ug/ml) of hS/p25, preS 1, or preS2 peptides.
For the study of T cell lines and clones, cloned T cells were washed extensively to remove IL-2 and FCS. Subsequently, 5 X 104 cells/well were incubated for 3 d with 1 X 105 mytomicin C-treated autologous PBMC as APC in complete medium in the presence of different concentrations of HBV envelope antigens, rHBcAg, or TT.
All proliferation assays were performed in triplicate and [3H]thymidine (0.5 uCi/well; sp act, 2.0 Ci/mmol; Amersham International, Amersham, UK) was added 18 h before harvesting. The results are expressed as the mean counts per minute ofthree replicate determinations and as the stimulation index (SI); that is, the ratio between mean counts per minute incorporated in the presence of antigen and mean counts per minute obtained in the absence of antigen.
Determination ofthefrequency ofHBVenvelope antigen-responsive T cells. Peripheral blood HBV envelope antigen-specific T cell frequency was determined by limiting dilution analysis. Varying numbers of purified T cells (1 X I05, 6 X 104, 3 X 104, 1 X 104, 3 X 103, 1 X 103, and 3 X 102) were seeded in individual wells of round-bottomed, 96well plates in the presence of a constant number of autologous mytomicin C-treated non-T cells (I X 104) and an optimal dose of antigen (1 Ag/Ml). 32 replicate wells were set up for each concentration ofresponder T cells in the presence or absence of antigen. [3H]Thymidine incorporation was measured after 7 d of incubation. Individual cultures stimulated with antigen, showing [3H]thymidine incorporation higher than the arithmetic mean plus 3 SD of that shown by cultures incubated in the absence of antigen were scored as positive and the fraction of nonresponder cultures was calculated for each concentration ofseeded T cells. Statistical analysis. Poisson analysis was applied for the calculation of T cell frequency (25, 26) . Assuming that antigen responsive cells (ARC) are randomly and independently distributed through the culture wells, the number of ARC per well follows a Poisson distribution. After performing a limiting dilution assay, one may plot the natural logarithm of the fraction of negative wells against number of cells per well plated; a straight line is expected if single-hit Poisson kinetics are operative. In this instance, one may then estimate the Poisson parameter u, and thereby the frequency ofARC. We used the ELIDA program of C. Taswell (26) , which incorporates linear regression analysis, for this estimation procedure.
Results
Peripheral blood T cell proliferative response to HBV envelope antigens. The response of peripheral blood T cells to plasmaderived S/p25 and synthetic preS 1 and preS2 peptides was studied in 14 selected vaccine recipients who developed high titers ofserum anti-HBs after booster immunization (anti-HBs titers 2 1:100,000).
All 14 subjects displayed a significant T cell proliferative response to S/p25; 8 responded to preSi, while only 1 showed a significant level of T cell proliferation to preS2 (Table I) .
No significant level of T cell proliferation to the HBV envelope antigens used in this study was observed in the 15 control subjects.
Frequency of HBV envelope antigen-responsive T cells. Limiting dilution analysis was performed -1 mo after booster immunization on peripheral blood T cells derived from vaccine recipients 3 and 12 (Table I) . * SI values have been used for statistical analysis.
Frequency of circulating S and preS 1-specific T cells was studied in recipient 12 using the plasma-derived S/p25 antigen preparation and the preS1 synthetic peptide (1-108). Frequency of preS2-reactive T cells was not determined since peripheral blood T cells from this subject appeared to be responsive to S/p25 and preSl but not to preS2 (Table I) .
Limiting dilution analysis of T cells from vaccine recipient 3 (see Table I ) was performed using hS/p25 and the plasma-derived antigen preparation containing S+preS2+preSl used for T cell cloning.
The antigen concentration of 1 gg/ml was used since preliminary experiments showed that optimal peripheral blood T cell proliferation was usually elicited by this antigen concentration. In vaccine recipient 12 the frequency of circulating preSl and S/p25-responsive T cells was 1 in 16,155 and 1 in 35,335, respectively. In vaccine recipient 12 S/p25-responsive T cells were 1 in 59,311 T cells, whereas S+preS2+preS 1-responsive T cells were 1 in 16,750 ( Fig. 1) .
Generation of HBV-envelope antigen-specific T cell lines. Two vaccine recipients (subjects 4 and 12 of Table I ) who displayed a strong T cell proliferation to HBV envelope antigens were selected for clonal analysis of the T cell response. 118 cloned lines (42 from subject 12 and 76 from subject 4) were generated and tested for proliferative response to hS+preS2+preSl. 29 (14 from subject 12 and 15 from subject 4) displayed a dose-dependent (0.01-5 gg/ml) proliferation to HBV envelope antigens (Table II and Fig. 2 ) and their antigen specificity was confirmed by the absence of response to rHBcAg and TT (data not shown).
Cell surface analysis of the HBV envelope antigen-specific T cell lines revealed that all were CD3+, CD4+, or CD8-.
HBV envelope region specificity of the T cell cloned lines.
Antigen specificity ofthe 29 HBV envelope antigen responsive T cell cloned lines was analyzed further by testing their capacity to recognize antigen preparations containing only S/p25 without preS region encoded determinants. 21 lines (72%) showed a significant level ofproliferative response upon stimulation with plasma-derived S/p25 of ad subtype; 13 were also tested with rS/p25 of ay subtype and all showed comparable levels of response (Table II) . Identical results were also obtained with four of these lines using an additional plasma-derived antigen preparation containing S/p25 ofay subtype (data not shown). This observation indicated that these cloned lines recognized common epitopes shared by the ad and ay subtypes of HBsAg, in keeping with previous reports (28). In contrast, eight lines (28%) did not proliferate to S/p25 of ad or ay subtypes at all the antigen concentrations tested (0.01, 0.1, or 1-5 ,ug/ml; Table II ).
Two different recombinant preparations consisting of either S+preS2 or S+preS2+preS 1 were used to investigate further the antigen specificity of the S/p25 nonresponsive lines. All five S/p25 nonresponsive lines from subject 12 and two S/p25 nonresponsive lines from subject 4 did not proliferate to antigen preparations containing preS2 without preS 1 determinants, whereas all of them displayed a dose-dependent proliferation to rS+preS2+preS 1 (Table III and Fig. 2) . These results showed that these lines were preSI specific.
In contrast, one S/p25 nonresponsive line from subject 4 responded equally well to both recombinant preparations, suggesting that this line was probably preS2 specific.
The preS region specificity of the S/p25 nonresponsive lines was finally confirmed using preSI and preS2 synthetic peptides. Six of seven tested lines showed selective proliferation to the synthetic peptide consisting of the entire preS 1 region, whereas 1 line (AL9) recognized only the peptide representing the entire amino acid sequence of the preS2 region 8,536 (9) N.T N.T. N.T.
HBV envelope responsive T cells (5 X 104) were stimulated with varying concentrations of antigen (0.0 1, 0. 1, 1, and 5 Ug/ml) in the presence of autologous APC. Proliferation in the presence of optimal concentrations (5 gg/ml) is shown. The results are expressed as the mean counts per minute of three replicate determinations. The SI is in parentheses since the results refer to different experiments. Underlined values represent significant proliferative responses. (Table III) . None of the S/p25-responsive lines recognized these preS peptides (data not shown).
Two lines specific for S/p25 (E16 and AL4) and one specific for preSI (E8) were selected for additional cloning at 0.5 cells/well. Of a total of 163 T cell clones generated, 17 (7 derived from line E16, 3 from line E8, and 7 from line AL4) were tested for their proliferative response to HBV envelope antigens, and all showed the same envelope region specificity (Table II) 98% probability of monoclonality for the T cell populations derived from E16, E8, and AL4, respectively.
Discussion
Production of anti-HBs antibodies after vaccination with plasma-derived or recombinant HBV envelope antigen preparations appears to confer protection against HBV infection. Experimental conditions are the same described in the legend of Table II .
It is well known that helper T cell activation plays an essential role for neutralizing antibody synthesis, since B cells are usually induced to produce antiviral specific antibodies only after activation of antigen-specific CD4+ T cells. While the functional features of HBsAg-specific CD4+ T cells isolated from vaccine recipients have already been analyzed in great detail (27) (28) (29) , the T cell response to preS antigens during natural HBV infection and after vaccination has been poorly characterized (16) (17) (18) (19) (20) .
Taking advantage of the presence of preS determinants in some widely used plasma-derived vaccine preparations (Pasteur vaccine) that have been shown to induce production of detectable levels of anti-preS antibodies in a proportion of recipients (9, 15) , we analyzed the T cell response to the S and preS envelope antigens of HBV elicited by these vaccines. For this purpose we used antigen preparations containing well-determined amounts ofS, preS2, and preS 1 region encoded polypeptides in an attempt to characterize the whole repertoire of different T cell specificities induced by the immunizing vaccine in the recipient individuals.
14 subjects who were high responders to vaccination in terms of in vivo anti-HBs specific antibody production were initially studied for their in vitro T cell responsiveness to S/p25, preSl, and preS2.
All subjects showed detectable levels of T cell sensitization to S/p25, whereas significant T cell response to preS2 was observed in only one vaccine recipient.
These results are not surprising if we consider that preS determinants represent < 2% of the total HBV envelope antigens contained in the Pasteur vaccine, which mainly consists of S region encoded polypeptides.
In contrast, > 50% of the vaccine recipients demonstrated a T cell proliferative response to preS 1 sequences, which are present in low quantity in the immunizing vaccine. These findings suggest that preSl may be highly immunogenic at the T cell level in man.
Additional evidence supporting the notion that preSl is a strong T cell immunogen came from the results ofthe limiting dilution experiments. Two vaccine recipients who showed a significant T cell response to preS1 were selected to evaluate the real magnitude of this phenomenon by limiting dilution analysis of the circulating HBV envelope-responsive T cells.
In the first vaccine recipient (No. 12, Table I ) frequency of preS 1-specific circulating T cells was surprisingly higher than that of S/p25 reactive T cells (1:16,155 vs. 1:35,335; Fig. 1 A) . This finding confirmed that preS 1-responsive T cells were not only present in the peripheral blood of this subject but also represented at a high level.
Limiting dilution analysis was performed in the second vaccine recipient (No. 3, Table I ) using hS/p25 and hS+preS2+preS1, assuming that a higher frequency of T cells responsive to the latter preparation should be due to the activation of preS-specific T cells. In line with the results of the first limiting dilution experiment, frequency of T cells responsive to S/p25 was less than one-third that of T cells responsive to hS+preS2+preSl, confirming the high frequency of circulating preS-region responsive T cells in this second vaccine recipient (Fig. 1 B) .
The frequency ofhuman peripheral blood T cell precursors specific for other antigens has been previously documented by limiting dilution analysis in several systems. Published frequency of TT reactive T cells in immune individuals ranged from -1:750 to 1:1 1,500 (30) . Similar frequencies were ob-served for T cells specific for purified protein derivative (30, 31) , streptokinase/streptodornase (32) , and keyhole limpet hemocyanin (33) in immune donors. Frequencies between 1:3,656 and 1:47,501 were found in response to M. leprae in patients with tuberculoid and lepromatous leprosy (31) .
Our results demonstrate that peripheral blood preSl-specific T cells may be more abundant than S/p25-specific T cells in some vaccine recipients of an HBV vaccine containing only trace quantities of the preSl antigen. This frequency appears to be close to that induced by T cell immunogens as powerful as TT and purified protein derivative administered at optimal doses. The significant level of T cell proliferation to S and preS determinants observed in some vaccine recipients prompted us to explore the possibility of producing S-and preS-responsive T cell clones from these individuals. 29 oligoclonal lines, responsive to the antigen preparation used for cloning containing hS+preS2+preSl, were produced from two vaccine recipients. 21 were S/p25 specific, 7 preS 1 specific, and 1 preS2 specific since they selectively recognized the amino acid sequences encoded by the S, preS 1, and preS2 regions of the HBV envelope, respectively.
It is remarkable that -25% of the HBV envelope-specific T cell lines (7 of 29) isolated by cloning from two individuals immunized with a vaccine containing very low amounts of preS determinants (c 20 ng/,g HBsAg) were preSl specific.
These results appear even more significant if we consider that preS 1 sequences were also present in very low quantities in the antigen preparation used for cloning (-1% of the total HBsAg). Therefore, these findings provide additional support to the evidence that preS 1 is highly stimulatory for human T cells.
In conclusion, the present study illustrates that immunization with very low quantities of preS 1 can induce significant T cell sensitization which is detectable as in vitro T cell proliferation to preS 1. In addition, results of limiting dilution analysis and T cell cloning confirm that preS 1-specific T cells may be present with high frequency in the peripheral blood of a proportion of preS 1 high responder subjects. Taken together, all these observations suggest that the product ofthe preSl region ofthe HBV envelope is a very good T cell immunogen in man, confirming previous reports in the mouse system (12). Functional analysis of T cell lines and clones described in this study could help to establish whether inclusion of higher quantities of preSl sequences in the hepatitis B vaccine can improve its efficacy. With respect to this matter, it also remains to be determined whether the preS 1 antigen is similarly immunogenic in low responders to the present plasma-derived hepatitis B vaccine.
